SCHEMBL4164853

SCHEMBL4164853

CS(=O)(=O)c1nn(-c2ccccc2)c2nc(-c3ccc(-c4cnc(N)cn4)cc3)n(-c3ccc(Cl)cc3)c(=O)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
TP53 P04637 2/20 0.43
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.41
GRM1 Q13255 4/20 0.41
GRM5 P41594 1/20 0.41
THRB P10828 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
PPARA Q07869 1/20 0.39
PTGS2 P35354 1/20 0.38
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
USP2 O75604 2/20 0.36
CYP1A2 P05177 2/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4170521 0.90 MAPT (0.43) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4164852 0.90 MAPT (0.44) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4174355 0.87 MAPT (0.44) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL1688912 0.87 MAPT (0.42) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4159236 0.85 MAPT (0.43) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL1688985 0.85 MAPT (0.42) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4167532 0.84 MAPT (0.52) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL1753271 0.84 MAPT (0.46) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL1689086 0.81 MAPT (0.43) MAPTTP53ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5612004 0.81 MAPT (0.43) MAPTTP53ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999132-B1 AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY IRM LLC (BM) 2012-07-18 EP claimed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US claimed
EP-1999132-A1 AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY IRM, LLC (BM) 2008-12-10 EP claimed
WO-2007120454-A1 AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY IRM LLC (BM) 2007-10-25 WO claimed
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
WO-2007120454-A1 AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY IRM LLC (BM) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity CNR1, CNR2, ITPR2 MAPT 2577/4885TP53 2988/4885ALDH1A1 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.